Romosozumab — on track or derailed?

Overview of attention for article published in Nature Reviews Endocrinology, October 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 42,420 followers.

RT @NatureRevEndo: Sundeep Khosla asks whether #romosozumab is on track or derailed (£) https://t.co/HFCAtsEQ2E #WorldOsteoporosisDay #oste…

Reply Repost Favourite

Featured in the December issue: #NewsandViews #Romosozumab — on track or derailed? | https://t.co/HFCAtsEQ2E (£)

Reply Repost Favourite

RT @NatureRevEndo: Sundeep Khosla asks whether #romosozumab is on track or derailed (£) https://t.co/HFCAtsEQ2E #WorldOsteoporosisDay #oste…

Reply Repost Favourite

RT @NatureRevEndo: Sundeep Khosla asks whether #romosozumab is on track or derailed (£) https://t.co/HFCAtsEQ2E #WorldOsteoporosisDay #oste…

Reply Repost Favourite

Sundeep Khosla asks whether #romosozumab is on track or derailed (£) https://t.co/HFCAtsEQ2E #WorldOsteoporosisDay #osteoporosis https://t.co/n75oeloTAm

Reply Repost Favourite

Just published: @MayoClinic's Sundeep Khosla asks whether #romosozumab is on track or derailed (£) https://t.co/HFCAtsEQ2E https://t.co/gIXuBwgjBt

Reply Repost Favourite